Amphastar Pharmaceuticals (AMPH) Short term Debt (2013 - 2026)

Amphastar Pharmaceuticals' Short term Debt history runs 14 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Short term Debt rose 645.98% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 645.98% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 601.28% from the prior year.
• Short term Debt climbed to $1.7 million in Q1 2026 per AMPH's latest filing, from $1.6 million in the prior quarter.
• Across five years, Short term Debt topped out at $12.9 million in Q2 2023 and bottomed at $224000.0 in Q1 2025.
• The 5-year median for Short term Debt is $927000.0 (2025), against an average of $1.8 million.
• Across the five-year window, Short term Debt tumbled 98.07% in 2024 and surged 645.98% in 2026, its largest moves.
• Year by year, Short term Debt stood at $3.0 million in 2022, then tumbled by 85.69% to $436000.0 in 2023, then slumped by 46.33% to $234000.0 in 2024, then soared by 601.28% to $1.6 million in 2025, then advanced by 1.83% to $1.7 million in 2026.
• Per Business Quant, the three latest AMPH Short term Debt figures stand at $1.7 million (Q1 2026), $1.6 million (Q4 2025), and $923000.0 (Q3 2025).